MedTrace Logo

Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

NCT04043702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-08-02

No results posted yet for this study

Summary

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).

.

Conditions

Interventions

DRUG

The intervention being studied

Intervention Other Names have not been specified

Sponsors & Collaborators

  • Ministry of Health and Population, Egypt

    lead OTHER_GOV

Principal Investigators

  • mahmoud younis, M.S · egyptian ministry of health

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2019-07-20
Completion
2019-07-29

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04043702 on ClinicalTrials.gov